FDA Update: Sotagliflozin Approved For Broad HF Treatment
WEBJun 5, 2023 · The U.S. Food and Drug Administration (FDA) on May 26 approved a new drug application submitted by Lexicon Pharmaceuticals, Inc. for sotagliflozin (Inpefa), the first dual SGLT1 and SGLT2 inhibitor for the treatment of heart failure (HF), including HF with preserved ejection fraction and HF with reduced ejection fraction.
SGLT2i Use Linked to Lower Risk for Neurodegenerative Disease in …
WEB1 day ago · References: Kim HK, Biessels GJ, Yu MH, et al. SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes. Neurology. 2024 Oct 22;103(8):e209805. doi:10. ...
SGLT2 inhibitor empagliflozin is shown to be safe and effective for ...
WEBSep 2, 2024 · The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction...
FDA approves first SGLT1/SGLT2 inhibitor for heart failure
WEBJun 29, 2023 · Patients now have an even better chance at survival with the recent FDA approval of Inpefa, the brand name of the drug sotagliflozin. It is the first sodium glucose cotransporter (SGLT) inhibitor that addresses glucose reabsorption in both the kidneys and the small intestine.
SGLT2 Inhibitors Cut Kidney Risks Across CKD, Heart Failure, …
WEB4 days ago · SGLT2 inhibitors reduce the risk for adverse kidney outcomes across most high-risk populations with CKD, heart failure, and/or type 2 diabetes. Sodium glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk for adverse kidney outcomes across patient groups with different combinations of chronic kidney disease (CKD), type 2 …
SGLT2 Inhibitors Reduce Cardiovascular Risks Independent of GLP …
WEBJun 20, 2024 · Sodium-glucose cotransporter 2 inhibitors (SGLT2i) improve cardiovascular and kidney outcomes in patients with type 2 diabetes with or without concomitant use of glucagon-like peptide-1...
KDIGO provided recommendations on SGLT2 inhibitors and …
WEBMay 12, 2023 · Sodium-glucose cotransporter-2 (SGLT2) inhibitors and nonsteroidal mineralocorticoid receptor antagonists (MRAs) are now recommended for more patients with chronic kidney disease (CKD), but data are needed on their cost-effectiveness, an ACP Journal Club commentary said.
Applications of SGLT2 inhibitors beyond glycaemic control
WEBApr 26, 2024 · Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of kidney disease progression in people with or without diabetes as well as the risk of acute kidney injury and...
SGLT2 inhibitors as the bedrock of therapy for heart failure
WEBSep 3, 2022 · Despite the differences in patient populations and study designs, the evidence is strikingly consistent and resoundingly clear—SGLT2 inhibitors are the bedrock of therapy for heart failure regardless of ejection fraction or care setting.
SGLT2 inhibitors: mechanisms of cardiovascular benefit beyond …
WEBJul 14, 2020 · Sodium–glucose cotransporter 2 (SGLT2) inhibitors are effective antidiabetic therapies in patients with type 2 diabetes mellitus and are associated with improved glycaemic control as well...
Skip to content